The authors recommend that newly diagnosed patients with AML should be screened for NPM1, FLT3, and CEBPA mutations, as the data from such analyses provide important prognostic information and may ...

Gene mutations in acute myeloid leukemia (AML) cells can guide treatment options, and machine learning can rapidly guess the ...

They discovered that specific mutations in the STAG2 protein cause altered DNA folding in the cell nucleus, thereby ...

High-throughput techniques to analyze the AML genome in greater depth have revealed novel mutations with putative roles in leukemogenesis. The use of prognostic biomarkers has allowed for a more ...

Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with ...

BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced ...

GenFleet will determine the next steps in development around lymphoma as SELLAS' focus remains on AML and spliceosome-chromatin mutations, including ASXL1 mutations. Raised $25.0 Million of Gross ...

The number of chromosomal alterations observed in AML [2,3] (more than 200 translocations, in addition to several point mutations) is enormous and makes it impossible to screen each one of them as ...

Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years after being rejected by ...

This study analyzed a prospectively collected cohort of 410 AML cases. It was led by Dr. Guilin Tang, and a team of experts from the MD Anderson Cancer Center, and is the first study known to utilize ...